CAM
GMAB icon

ClariVest Asset Management’s Genmab GMAB Stock Holding History

ClariVest Asset Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13
Closed -$398 – 884
2024
Q1 		$398 Buy
13
+3
+30% +$88 ﹤0.01% 821
2023
Q4 		$320 Buy
+10
New +$314 ﹤0.01% 859

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClariVest Asset Management's GMAB Position: Q2 2024 in Review

ClariVest Asset Management sold out of Genmab (GMAB) in Q2 2024, closing a stake of 13 shares — an estimated $398 sold.

ClariVest Asset Management first reported a position in GMAB in Q4 2023 and held it in 2 quarters. The position peaked at $398 in Q1 2024. 220 funds tracked by Wall St. Rank hold GMAB as of Q2 2024.

  • ClariVest Asset Management reported no remaining Genmab position as of Q2 2024 after selling out during the quarter.
  • ClariVest Asset Management sold 13 Genmab shares in Q2 2024, an estimated $398.
  • ClariVest Asset Management first reported a position in Genmab in Q4 2023 and held it in 2 quarters.
  • ClariVest Asset Management's Genmab position peaked at $398 in Q1 2024.
  • 220 funds tracked by Wall St. Rank held Genmab as of Q2 2024.

Based on ClariVest Asset Management's 13F filing for Q2 2024, filed 7 Aug 2024.